Benefits, Harms, and Costs of Osteoporosis Screening in Male Veterans
Abstract
This is a propensity score matched observational study using CMS and VA data from January 1, 2000-December 31,mean follow-up 4.7 years. Men receiving VA primary care aged 65-99 without prior fracture (n=2,539,812) were included. Men receiving DXA were 1:3 matched with untested controls by propensity scores indicating the probability of DXA testing within the next year. Time to first clinical fracture was the primary outcome. Co-morbidities, demographics, medications, DXA results, and osteoporosis treatment were defined using administrative data and natural language processing. Landmark analysis with competing risk compared time to fracture. During follow-up of 183,943 men tested with DXA and475,449 controls, 9.4 fractured and 20.6 died. DXA testing overall was not associated with a decrease in fractures; conclusions are limited by unmeasured confounders and low medication initiation and adherence in those meeting treatment thresholds (12 of follow-up time). Mortality was 21 lower in DXA tested men, also likely related to unmeasured confounders and selection bias. In contrast, DXA testing in pre-specified subgroups was associated with lower risk of fracture compared to the overall DXA population: androgen deprivation therapy (HR 0.77, 0.66-0.89);glucocorticoids (0.77, 0.72-0.84); age > 80 years (0.85, 0.81-0.90); one or more VA guideline risk factors (0.91, 0.87-0.95);and high FRAX- BMI (0.90, 0.86-0.95). Total costs were slightly higher for DXA treated men than untested men; cost effectiveness analysis was not completed due to the overall lack of benefit of DXA testing. We conclude that current VADXA testing practices are ineffective overall; interventions to improve treatment adherence are needed. Targeted DXA testing of higher risk men was associated with lower fracture risk.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2017
- Accession Number
- AD1053962
Entities
People
- Cathleen S. Colon-emeric
- Megan Pearson
Organizations
- Institute for Medical Research